^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    STK-009/SYNCAR-001

    i
    Associations
    News

    Trials

    Company:
    Synthekine
    Drug class:
    CD19-targeted CAR-T immunotherapy, IL-2 stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies (NCT05665062)
    Phase 1
    Synthekine
    Recruiting
    Last update posted :
    03/21/2024
    Initiation :
    06/24/2022
    Primary completion :
    06/24/2026
    Completion :
    11/01/2026
    CD19
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • STK-009/SYNCAR-001